Endocrine Abstracts

Background: Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) which is widely used for the management of type 2 diabetes as well as for the obesity treatment. Evidence suggest that the level of HbA1c reduction and weight loss with oral semaglutide were similar to those of the subcutaneous formulation1. However, oral formulation not only improves the patient’s compliance to treatment but also makes it a favourable option for those who are relu...